• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    5/30/25 4:15:23 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    upxi_8k.htm
    0001775194false00017751942025-05-292025-05-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    ________________________

     

    FORM 8-K

    ________________________

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 29, 2025

     

     

    UPEXI, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Nevada

     

    001-40535

     

    83-3378978

    (State or Other Jurisdiction of Incorporation)

     

    (Commission File Number)

     

    (I.R.S. Employer Identification No.)

     

    3030 N. Rocky Point Drive, Suite 420

    Tampa, FL 33607

    (Address of Principal Executive Offices) (Zip Code)

     

    (701) 353-5425

    (Registrant's telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

    _______________________________

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.001

     

    UPXI

     

    NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 7.01 Regulation FD Disclosure

     

    Item 8.01 Other Events.

     

    On May 29, 2025, Upexi, Inc. (the “Company”) issued a press release. The Company announced that it has selected GMI Digital as its crypto-native marketing and design service provider. A copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    On May 30, 2025, the Company issued a press release announcing that management will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025 on June 24 and 25, 2025. A copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein.

     

    The information in Item 7.01 and Item 8.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing.

     

    Section 9 – Financial Statements and Exhibits

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.

    Exhibit Description

    99.1

    Press Release of Upexi, Inc., dated May 29, 2025

    99.2

     

    Press Release of Upexi, Inc., dated May 30, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL Document)

     

     
    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    UPEXI, INC.

     

     

     

     

     

    Dated: May 30, 2025

     

    /s/ Andrew J. Norstrud

     

     

     

    Name: Andrew J. Norstrud

     

     

     

    Title: Chief Financial Officer

     

     

     
    3

     

    Get the next $UPXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Upexi to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25

      TAMPA, Fla., May 30, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that management will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025 on June 24 and 25, 2025. iAccess Alpha Virtual Conference Details:Date: June 24-25, 2025Presentation Date and Time: Tuesday, June 24th at 12:30 p.m. ETWebcast: https://ir.upexi.com/news-events/ir-calendar To schedule a one-on-one meeting with Upexi, please contact KCSA Strategic Communications at [email protected]. About Upex

      5/30/25 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused Strategy

      TAMPA, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that it has selected GMI Digital as its crypto-native marketing and design service provider. As Upexi advances its Solana-first strategy—offering investors scalable, transparent, and compliant exposure to $SOL—GMI Digital will lead initiatives across brand identity, digital presence, product UX/UI, and social media storytelling. The collaboration aims to sharpen Upexi's narrative and strengthen its engagement with both institutional and crypto-native a

      5/29/25 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 million

      Purchases 77,879 locked SOL for $11.8 million Upexi now has 679,677 SOL, valued at $121.2 million at the current price of $178.261 TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced it purchased 77,879 locked SOL at $151.50 each for a total of $11.8 million. At the current $178.26 price of SOL, this represents a $2.1 million, or 17.7%, built-in gain for investors. Upexi now holds 679,677 SOL, acquired for $96.5 million and valued at $121.2 million, for a gain of $24.5 million inclusive of both

      5/28/25 9:08:35 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    SEC Filings

    See more
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/30/25 4:15:23 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/28/25 5:05:11 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/28/25 5:00:19 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care